Iparomlimab
Immune Checkpoint Inhibitors
Tianjin Medical University Cancer Institute and HospitalPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
10 Active assets in the Immune Checkpoint Inhibitors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
rc48-adc First Affiliated Hospital of Guangxi Medical University | Phase 3 | B |
Pyrotinib First Affiliated Hospital of Guangxi Medical University | Phase 3 | B |
CIS-DIAMMINEDICHLOROPLATINUM II Tianjin Medical University Cancer Institute and Hospital | Phase 2 | CCC |
Adebrelimab Sun Yat-sen University | Phase 2 | CCC |
Rivoceranib Hunan Cancer Hospital | Phase 2 | CCC |
View all 11 →
Same molecule, other indications
Iparomlimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →